SAN FRANCISCO -- Treatment with the PARP inhibitor talazoparib (Talzenna) plus enzalutamide (Xtandi) significantly improved radiographic progression-free survival (rPFS) compared with enzalutamide ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window CHICAGO -- ...

Using advanced computational genomics, Johns Hopkins investigators discovered how prostate cancer develops resistance to ...

A phase 2 exploratory study of men with low- and intermediate-risk localized prostate cancer demonstrated the oncologic benefit of enzalutamide treatment vs active surveillance. Among men with low- or ...

Sexual function data support enzalutamide as monotherapy and combined with leuprolide in patients with high-risk biochemically recurrent prostate cancer. Enzalutamide monotherapy maintains sexual ...

Please provide your email address to receive an email when new articles are posted on . Enzalutamide plus leuprolide and enzalutamide alone significantly extended MFS vs. leuprolide and placebo.

Credit: Getty Images. A regulatory decision is expected in the fourth quarter of 2023. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application ...

Adding enzalutamide (Xtandi) to androgen deprivation therapy (ADT) can extend metastasis-free survival while maintaining quality of life in men with prostate cancer who have a high risk for ...

Already approved for the treatment of metastatic castration-resistant prostate cancer, enzalutamide (Xtandi, Pfizer/Astellas) may soon join apalutamide (Erleada, Janssen) for treating earlier prostate ...

Enzalutamide (Xtandi, Astellas) is an androgen receptor antagonist that acts on the androgen receptor signalling pathway to decrease the proliferation of cancer cells and induce cancer cell death. It ...

Newly published results of two independent studies have demonstrated the benefits of treatment with the androgen receptor inhibitor enzalutamide in the setting of metastatic castration-resistant ...